文献速递内脏/肾动脉与血管畸形

慢性肠系膜缺血的开放与腔内修复术的长期价值

Long-term value in open and endovascular repair of chronic mesenteric ischemia.
PubMed 文献 · J Vasc Surg · 2023-09-12

本研究利用纽约州全支付方数据库,对2000年至2014年接受干预的慢性肠系膜缺血患者进行倾向性评分匹配,比较开放修复术与腔内修复术的5年价值。匹配后每组209例,腔内修复术组5年价值更高(8.04±11.42生命年/10万美元费用 vs 4.89±5.28生命年/10万美元费用,P<.01),但再干预更多、无再干预生存率更低。作者认为在解剖条件合适时,腔内修复术可被验证为慢性肠系膜缺血的首选治疗。

要点

  • 匹配后腔内修复术组5年价值高于开放修复术组(8.04±11.42 vs 4.89±5.28生命年/10万美元费用,P<.01)。
  • 腔内修复术组再干预37例 vs 开放修复术组17例(P<.01),再干预次数55次 vs 19次(P<.01)。
  • 5年生存率两组无显著差异(腔内修复术组59.6±3.76% vs 开放修复术组62.3%±3.49%,P=.91)。

核心结论

  • 尽管再干预增加且无再干预生存率更低,慢性肠系膜缺血患者接受腔内修复术的5年价值更高。
  • 与价值负相关的因素为开放修复术、年龄、重症监护室住院天数、充血性心力衰竭、心律失常和癌症。
  • 作者认为在解剖条件合适时,腔内修复术可被验证为慢性肠系膜缺血的首选治疗。

研究设计与样本

  • 研究数据来自纽约州全支付方数据库(Statewide Planning and Research Cooperative System),查询国际疾病分类第九版编码为慢性肠系膜缺血的患者,排除急性缺血病例。
  • 使用Charlson合并症指数、年龄、性别、种族、肾功能和肺部疾病进行倾向性评分匹配,最终每组209例。
  • 采用多元线性回归和混合效应线性回归分析5年价值相关因素,价值以生命年/10万美元费用计算,并进行Kaplan-Meier生存和无再干预生存估计。

主要发现

  • 2000年至2014年共有875例患者因慢性肠系膜缺血接受干预,其中209例(28.1%)接受开放修复术,535例(71.9%)接受腔内修复术。
  • 倾向性评分匹配后(每组209例),腔内修复术组术后5年价值高于开放修复术组(8.04±11.42生命年/10万美元费用 vs 4.89±5.28生命年/10万美元费用,P<.01)。
  • 腔内修复术组再干预患者更多(37例 vs 17例,P<.01),再干预次数为55次 vs 19次(P<.01)。
  • 5年生存率腔内修复术组为59.6±3.76%,开放修复术组为62.3%±3.49%(P=.91);5年无再干预生存率腔内修复术组为43.7±3.86%,开放修复术组为58.1±3.53%(P=.04)。

关键数值与推荐

  • 5年价值:腔内修复术组8.04±11.42生命年/10万美元费用 vs 开放修复术组4.89±5.28生命年/10万美元费用(P<.01)。
  • 再干预患者数:腔内修复术组37例 vs 开放修复术组17例(P<.01);再干预次数:腔内修复术组55次 vs 开放修复术组19次(P<.01)。
  • 5年生存率:腔内修复术组59.6±3.76% vs 开放修复术组62.3%±3.49%(P=.91)。
  • 5年无再干预生存率:腔内修复术组43.7±3.86% vs 开放修复术组58.1±3.53%(P=.04)。

临床怎么用

  • 指南推荐对较年轻、较健康的慢性肠系膜缺血患者优先选择开放修复术而非腔内修复术。
  • 作者认为在解剖条件合适时,腔内修复术可被验证为慢性肠系膜缺血的首选治疗,依据是更高的手术价值。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Guidelines recommend open revascularization (OR) over endovascular revascularization (ER) for the treatment of chronic mesenteric ischemia (CMI) for younger, healthier patients. However, little is known about the long-term costs of these recommendations with respect to patients' overall life expectancy. This study investigated whether 5-year value differs between these treatment modalities. METHODS: Patient data were extracted from the Statewide Planning and Research Cooperative System, the New York statewide all-payor database containing demographics, diagnoses, treatments, and charges. The database was queried for patients with an International Classification of Diseases, ninth revision, code for CMI, with the specific exclusion of acute ischemia cases. A propensity score match was performed using the Charlson Comorbidity Index, age, sex, race, renal status, and pulmonary disease for the final cohort of patients. Multiple linear regression and mixed effects linear regression were used to determine factors associated with 5-year value, calculated as life-years/$100k in charges. Charges were gathered from the index admission and subsequent admissions for acute or CMI, mesenteric angiography, or follow-up reintervention. Kaplan-Meier estimation was performed for survival and reintervention-free survival. RESULTS: From 2000 to 2014, 875 patients underwent intervention for CMI. Of those meeting inclusion criteria, 209 (28.1%) underwent OR and 535 (71.9%) ER. After propensity score matching (n = 209 in each group), the ER group showed higher value at 5 years after the procedure (8.04 ± 11.42 life-years/$100k charges vs 4.89 ± 5.28 life-years/$100k charges; P < .01). More patients underwent reintervention in the ER group (37 patients vs 17 patients; P < .01), with 55 reinterventions in the ER group and 19 in the OR group (P < .01). Multiple linear regression analysis showed that age, congestive heart failure, dysrhythmia, cancer, and days spent in the intensive care unit were negatively associated with value at 5 years, whereas ER was positively associated. Survival was 59.6 ± 3.76% vs 62.3% ± 3.49% at 5 years (P = .91), and reintervention-free survival was 43.7 ± 3.86% vs 58.1 ± 3.53% (P = .04), for ER and OR respectively. CONCLUSIONS: Despite increased reinterventions and lower reintervention-free survival, the value for patients with CMI was higher in those who underwent ER in the largest propensity score-matched cohort to date looking at long-term value. Factors negatively associated with value were OR, age, days in intensive care, congestive heart failure, dysrhythmia, and cancer. In patients with amenable anatomy, ER is validated as the first-choice treatment for CMI based on the superior procedural value.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Lehane D, Geiger J, Kedwai B, et al. Long-term value in open and endovascular repair of chronic mesenteric ischemia. J Vasc Surg. 2023. PMID: 37709177. doi:10.1016/j.jvs.2023.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。